Literature DB >> 30029677

Dysregulation of human NEFM and NEFH mRNA stability by ALS-linked miRNAs.

Danae Campos-Melo1, Zachary C E Hawley1, Michael J Strong2,3,4,5.   

Abstract

Neurofilaments (NFs) are the most abundant cytoskeletal component of vertebrate myelinated axons. NFs function by determining axonal caliber, promoting axonal growth and forming a 3-dimensional lattice that supports the organization of cytoplasmic organelles. The stoichiometry of NF protein subunits (NFL, NFM and NFH) has to be tightly controlled to avoid the formation of NF neuronal cytoplasmic inclusions (NCIs), axonal degeneration and neuronal death, all pathological hallmarks of amyotrophic lateral sclerosis (ALS). The post-transcriptional control of NF transcripts is critical for regulating normal levels of NF proteins. Previously, we showed that miRNAs that are dysregulated in ALS spinal cord regulate the levels of NEFL mRNA. In order to complete the understanding of altered NF expression in ALS, in this study we have investigated the regulation of NEFM and NEFH mRNA levels by miRNAs. We observed that a small group of ALS-linked miRNAs that are expressed in human spinal motor neurons directly regulate NEFM and NEFH transcript levels in a manner that is associated with an increase in NFM and NFH protein levels in ALS spinal cord homogenates. In concert with previous observations demonstrating the suppression of NEFL mRNA steady state levels in ALS, these observations provide support for the hypothesis that the dysregulation of miRNAs in spinal motor neurons in ALS fundamentally alters the stoichiometry of NF expression, leading to the formation of pathological NCIs.

Entities:  

Keywords:  ALS; Motor neuron; NEFH; NEFM; Neurofilament; miRNA

Mesh:

Substances:

Year:  2018        PMID: 30029677      PMCID: PMC6054723          DOI: 10.1186/s13041-018-0386-3

Source DB:  PubMed          Journal:  Mol Brain        ISSN: 1756-6606            Impact factor:   4.041


Introduction

Neurofilaments (NFs) are unique neuron-specific intermediate filaments in vertebrates. They are highly dynamic structures that determine axonal caliber, promote axonal growth and organize the cytoplasm to form a stable 3-dimensional lattice that supports the organization of organelles and cytoplasmic proteins [1, 2]. NF subunit proteins (low, medium and high molecular weight neurofilaments; NFL, NFM and NFH, respectively) form homo- and hetero-polymers following a specific stoichiometry and tight spatiotemporal regulation. Conserving NF stoichiometry by controlling the levels of expression of individual NF subunits is critical for the maintenance of healthy neurons. Alterations of NF mRNA steady stoichiometry and the associated formation of neuronal cytoplasmic inclusions (NCIs) composed of NF proteins are neuropathological markers of degenerating motor neurons in amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease [2-4]. Although the exact mechanism by which NF NCIs exert toxicity is unknown, it has been suggested that they alter the internal structure of axons and disrupt axonal transport, in addition to impairing NMDA-mediated calcium influx, compromising the survival of neurons [4, 5]. Post-transcriptional control is crucial for preserving NF subunit expression in neuronal homeostasis and also during axonal outgrowth in development and regeneration [6-8]. MiRNAs are evolutionary conserved non-coding RNAs that control the expression of the majority of the mammalian transcriptome and have been increasingly linked to neurodegenerative disorders. We and others have described a profound dysregulation of miRNAs in spinal cord and motor cortex of ALS patients [9-12]. We previously demonstrated that a selective group of these miRNAs directly regulate NEFL mRNA stability [9], and postulated that this dysregulation of miRNA expression would contribute to the selective suppression of NEFL mRNA levels observed in ventral lateral spinal cord motor neurons in ALS [13, 14]. Proper control of the levels of the NF triplet is critical because the backbone of the NF is mainly formed by NFL [15] and the stoichiometry of NFL/NFM/NFH (4:2:1) has to be carefully maintained [16]. The miRNAs responsible for regulating human NEFM and NEFH mRNA stability are however unknown. In this study we observed that a limited number of ALS-linked miRNAs that are expressed in spinal motor neurons directly regulate NEFM and NEFH mRNA levels, in a way that might explain the increase in NFM and NFH protein levels that we observed in ALS spinal cords and thus contribute directly to the formation of NF NCIs.

Methods

Tissue

Spinal cord samples from sALS patients (median age of death, 60.6 +/- 3.5 yrs) and age-matched, neuropathologically healthy control individuals (median age of death, 67.2 +/- 3.5 yrs) were used. All ALS cases were both clinically and neuropathologically confirmed using the El Escorial Criteria (World Federation of Neurology Research Group on Neuromuscular Disease, 1994). Written consent for autopsy was obtained from the next of kin at the time of death or from the patient antemortem in accordance with the London Health Sciences Centre consent for autopsy. ALS cases were genotyped and confirmed to have no known mutations in SOD1, TARDBP, FUS or expanded repeats in C9orf72 (Table 1).
Table 1

Patient demographics

CasesGenderAge of symptom onset (years)Symptom onsetAge of death (years)Cause of Death
C1F62Heart attack
C2M74Stroke
C3F68NA
C4M67NA
C5M75NA
C6F74Leukemia
C7M68Brain tumor
C8F53Pneumonia
A1F58NA60NA
A2M69Upper/lower limbs72NA
A3F40Bulbar41Systemic failure
A4M55NA61Pneumonia
A5M64Upper/lower limbs67Respiratory failure
A6M69Respiratory symptoms71Respiratory failure
A7F63NA64NA
A8F47Bulbar49Respiratory failure

NA: Not available

Patient demographics NA: Not available

3’RACE PCR, cloning and miRNA target prediction

NEFM and NEFH mRNA 3’UTRs were obtained using 3’RACE PCR. Briefly, TRIzol reagent (Thermo Fisher Scientific) was used for total RNA extraction from human spinal cord tissue. 3’RACE PCR was performed using SMARTer RACE 5′/3’ RACE Kit (Takara Bio. Inc., Clontech) and primers hNEFM_3RACE_F1D: 5’CACTTCACACGCCATAGTAAAGGAAGTCACC3′ and hNEFH_3RACE_F2: 5’GAGAAGGCCACAGAAGACAAGGCCGCCAAG3’ for NEFM and NEFH 3’UTRs, respectively. 3’UTR isoforms were cloned into pGEMT-Easy vector and sequenced. For luciferase assays, 3’UTRs were subcloned into pmirGLO vector between NheI and SalI sites and linked to the firefly luciferase coding region. Mutations in two nucleotides at the 3’end of each miRNA recognition element (MRE) within the NEFM and NEFH 3’UTRs were made using QuikChange Site-Directed Mutagenesis Kit II (Agilent) according to the manufacturer’s instructions. Mutations were carefully designed to ensure no changes were made in the secondary structures of the transcripts using the RNAFold WebServer (http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi). Both TargetScan (http://www.targetscan.org/) and miRanda (http://www.microrna.org/microrna/getGeneForm.do) software programs were used to determine miRNAs with predicted MREs in either NEFM or NEFH 3’UTRs.

miRNA extraction and real-time PCR

Total miRNA extraction using the mirVana miRNA isolation kit (Thermo Fisher Scientific) was performed from human ventral lumbar spinal cord using 5 controls and 8 ALS tissue samples according to the manufacturer’s instruction. Yield and purity of the miRNA solution was determined using spectrophotometry while RNA integrity was measured using a bioanalyzer instrument. MiRNA extracts from the spinal cord of ALS patients or controls were reversed transcribed and then subjected to real-time PCR using the miRCURY LNA™ Universal RT microRNA PCR (Exiqon) and ExiLENT SYBR Green master mix (Exiqon), according to the manufacturer’s instructions. PCRs were performed using the 7900 HT real-time PCR system. Relative expression of miRNAs was normalized to miR-16-5p, a miRNA previously demonstrated to have the same expression in sALS and controls [9]. The analysis of the relative expression of candidate miRNAs between sALS and controls was done using the ΔΔCT method, where fold-change was calculated as 2-ΔΔCT. All experiments were run in triplicate and significance was determined using Student’s t-test.

TaqMan real-time PCR

To examine the expression levels of NEFM and NEFH mRNA, total RNA extraction was performed on 6 ALS patient and 6 control lumbar spinal cord samples using TRIzol reagent (Ambion, Life Technologies). RNA samples were subjected to a cDNA synthesis reaction using the SuperScript IV VILO reverse transcriptase (Invitrogen, Thermo Fisher Scientific) in accordance to the manufactures instructions. Real-time PCR was done on the cDNA templates using the TaqMan Fast Advanced Master Mix and TaqMan Gene Expression Assays (Applied Biosystems, Thermo Fisher Scientific) targeting either NEFM or NEFH. Assays were performed in accordance to the manufactures instructions. TaqMan probes which either targeted NEFM or NEFH were designed with a FAM fluorophore. The expression of NEFM and NEFH were normalized to the expression of a reference gene (HPRT1), which was targeted by a TaqMan probe containing a VIC fluorophore. Changes in NEFM and NEFH mRNA expression between ALS patients and control subjects were determined using the ΔΔCT method, where fold-change was calculated as 2-ΔΔCT. Experiments were run in triplicate and determined to be significantly different using a Student’s t-test.

Fluorescent in situ hybridization (FISH)

To ensure that the miRNAs of interest are expressed in human motor neurons, neuropathologically normal lumbar spinal cord from control subjects was examined for miRNA expression. Tissue sections were formalin-fixed, paraffin embedded (FFPE) and cut into 7 μm sections. Samples were UV treated overnight to reduce the lipofuscin-induced auto-fluorescent signal. FISH was performed as described previously (Planell-Sauger et al. 2010). LNA probes were designed with double DIG-labels that targeted the miRNA of interest (Exiqon). DIG-HRP secondary antibody, and Tyramide Signal Amplification (TSA) Systems tagged with a Cy3 fluorophore (PerkinElmer) were used to obtain a fluorescent signal of the miRNA target. Ventral horn of human lumbar spinal cord tissue was examined for positive staining within motor neurons using the Olympus FV1000 confocal microscope.

Cell culture, luciferase assay and relative quantitative RT-PCR

HEK293T cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), at 37 °C with 5% CO2. HEK293T cells were plated on 96-well plates with a density of 10,000 cells/well 24 h prior to transfection. 100 nM of miRNA mimics (Thermo Fisher Scientific) and 3.47 fmol of pmirGLO containing NEFM or NEFH 3’UTR were co-transfected into the cells using Lipofectamine 2000 reagent (Thermo Fisher Scientific). Luciferase assays and relative quantitative RT-PCR were performed 24 h post-transfection as was described previously [17]. Data show positive values as up-regulation and negative values as down-regulation. All experiments were run in triplicate, and significance was determined using a Student’s t-test or one-way ANOVA followed by Turkey’s post hoc test.

Western blot

Total protein extraction from ventral lumbar spinal cord of 3 controls and 6 ALS patients was performed using NP40 lysis buffer containing proteinase inhibitors. Samples were sonicated, resuspended in loading buffer, denatured at 90 °C and run on an 8% SDS-gel. After transfer, the nitrocellulose membrane was probed with either mouse anti-NFM (1:1000; Boehringer Mannheim, 814–334), mouse anti-NFH (1:1000; Boehringer Mannheim, 814–342), or rabbit anti-GAPDH (1:5000; Abcam, ab9485) and later with HRP-secondary antibody (goat anti-mouse 1:3000, or goat anti-rabbit 1:5000; BioRad and Invitrogen, respectively). Relative protein expression of NFM and NFH were normalized to GAPDH expression levels. Student’s t-test was used to determine statistical differences in endogenous protein expression.

Results

Considering that 3’UTR polymorphisms have been increasingly reported in the literature, we determined if 3’UTR variants of NEFM and NEFH mRNAs are expressed in human spinal cord. A single variant form of NEFM and NEFH 3’UTRs (486 and 583 nt, respectively) was detected in lumbar spinal cord control tissue (Fig. 1). Analysis of ALS patients showed no difference in the 3’UTR variants of NEFM and NEFH expressed in spinal cord compared to control samples (data not shown).
Fig. 1

Single NEFM and NEFH mRNA 3’UTR variants are expressed in human spinal cord. 3’RACE-PCR was performed from spinal cord tissue samples of control individuals using specific primers to amplify NEFM and NEFH 3’UTRs. 3’UTRs were cloned and sequenced. One 3’UTR variant for each NEFM (486 nt) and NEFH (583 nt) transcript was observed in human spinal cord regardless of control or ALS origin of tissue. NEFM specific primer anneals to a region 40 nt upstream the stop codon

Single NEFM and NEFH mRNA 3’UTR variants are expressed in human spinal cord. 3’RACE-PCR was performed from spinal cord tissue samples of control individuals using specific primers to amplify NEFM and NEFH 3’UTRs. 3’UTRs were cloned and sequenced. One 3’UTR variant for each NEFM (486 nt) and NEFH (583 nt) transcript was observed in human spinal cord regardless of control or ALS origin of tissue. NEFM specific primer anneals to a region 40 nt upstream the stop codon Prediction algorithms showed that NEFM and NEFH 3’UTRs have multiple MREs for different pools of miRNAs. However, for this study we only considered those miRNAs that we previously observed to be differentially expressed in ALS tissue versus controls using the TaqMan assay [9]. We performed real-time PCR using SYBR green of 40 miRNAs to validate differential expression of 6 miRNAs that have MREs in NEFM or NEFH 3’UTRs (Fig. 2a). Each miRNA, (miR-92a-3p, miR-125b-5p, miR-9-5p, miR-20b-5p and miR-223-3p and miR-519d-3p) showed significant down-regulation of expression in ALS spinal cord versus controls (Fig. 2b).
Fig. 2

MiRNAs that have MREs in NEFM or NEFH 3’UTRs are down-regulated in the spinal cord of ALS patients. a MREs within NEFM and NEFH 3’UTRs of ALS-linked miRNAs. b Real-time PCR using SYBR green. Validation of differential expression in ALS versus control spinal cords of 6 miRNAs that have MREs in NEFM or NEFH mRNA 3’UTRs is shown. Experiments were performed in triplicate. Values below 1 indicate downregulation. Results are shown as mean ± SEM (Student t-test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05. MiR-9-5p, p = 0.0229; miR-20b-5p, p = 0.0230; miR-92a-3p, p = 0.0234; miR-125b-5p, p = 0.0412; miR-223-3p, p = 0.0215 and miR-519d-3p, p = 0.0232)

MiRNAs that have MREs in NEFM or NEFH 3’UTRs are down-regulated in the spinal cord of ALS patients. a MREs within NEFM and NEFH 3’UTRs of ALS-linked miRNAs. b Real-time PCR using SYBR green. Validation of differential expression in ALS versus control spinal cords of 6 miRNAs that have MREs in NEFM or NEFH mRNA 3’UTRs is shown. Experiments were performed in triplicate. Values below 1 indicate downregulation. Results are shown as mean ± SEM (Student t-test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05. MiR-9-5p, p = 0.0229; miR-20b-5p, p = 0.0230; miR-92a-3p, p = 0.0234; miR-125b-5p, p = 0.0412; miR-223-3p, p = 0.0215 and miR-519d-3p, p = 0.0232) Next, we examined the neuronal expression of the group of miRNAs that potentially regulate NEFM and NEFH transcripts in human spinal cord motor neurons of control tissue through FISH. MiR-92a-3p is almost exclusively expressed in motor neurons of spinal cord. MiR-125b-5p, miR-9-5p, miR-20b-5p and miR-519d-3p showed higher expression in motor neurons than in other cell types within the spinal cord. MiR-223-3p showed similar expression in motor neurons and surrounding cells. MiR-548c-3p was used as a negative control and miR-124-3p, which is highly expressed in neurons, was used as positive control. In summary, we observed that the 6 ALS-linked miRNAs that are predicted to regulate NEFM and NEFH mRNAs are expressed in motor neurons of human spinal cord (Fig. 3).
Fig. 3

MiRNAs that have MREs within NEFM or NEFH 3’UTRs are expressed in motor neurons of human spinal cord control tissue. FISH was performed using FFPE control spinal cord tissue and LNA™-enhanced detection probes 5’-DIG and 3’-DIG labeled for miRNAs. Amplification was performed using anti-DIG-HRP and TSA Plus Cy3. MiR-548c-3p, which is not expressed in human spinal cord, was used as negative control. MiR-124-3p, which is known as highly expressed in neurons, was used as positive control

MiRNAs that have MREs within NEFM or NEFH 3’UTRs are expressed in motor neurons of human spinal cord control tissue. FISH was performed using FFPE control spinal cord tissue and LNA™-enhanced detection probes 5’-DIG and 3’-DIG labeled for miRNAs. Amplification was performed using anti-DIG-HRP and TSA Plus Cy3. MiR-548c-3p, which is not expressed in human spinal cord, was used as negative control. MiR-124-3p, which is known as highly expressed in neurons, was used as positive control Functionality assays of these 6 miRNAs showed that miR-92a-3p and miR-125b-5p down-regulate the levels of a luciferase reporter linked to NEFM 3’UTR (Fig. 4a). MiR-9-5p, miR-20b-5p, miR-92a-3p and miR-223-3p down-regulate the levels of the luciferase reporter coupled to NEFH 3’UTR (Fig. 4b). We observed that most of these miRNAs also significantly down-regulate mRNA levels of the luciferase reporter bound to either NEFM or NEFH 3’UTR (Fig. 4c and d), which implies that miRNAs are dysregulating the stability of NEFM and NEFH transcripts. Reporter gene assay using NEFM or NEFH 3’UTR MRE mutants showed a decrease in the down-regulatory effect of each miRNA compared with the wild type, indicating that miR-9-5p, miR-20b-5p, miR-92a-3p, miR-125b-5p and miR-223-3p directly regulate NEFM or NEFH 3’UTRs stability (Fig. 5a and b).
Fig. 4

A group of ALS-linked miRNAs regulate a luciferase reporter linked to NEFM or NEFH 3’UTRs. HEK293T cells were co-transfected with a reporter plasmid containing NEFM or NEFH 3’UTRs and miRNA mimics. a, b Reporter gene assays were performed 24 h after transfection. Data are expressed as relative change and plotted in logarithmic scale. c, d Relative quantitative RT-PCRs were performed after RNA extraction, 24 h post-transfection. Data are expressed as relative mRNA level change and plotted in logarithmic scale. All experiments were performed in triplicate. Results are shown as mean ± SEM (Student t-test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, relative to the pmirGLO vector control). Reporter gene assays: miR-92a-3p/NEFM, p < 0.0001; miR-125b-5p/NEFM, p = 0.0005; miR-let-7a/NEFM, p = 0.6015; miR-9-5p/NEFH, miR-20b-5p/NEFH, miR-92a-3p/NEFH and miR-223-3p/NEFH, p < 0.0001; miR-519d-3p/NEFH, p = 0.0723; miR-let-7a/NEFH, p = 0.0893. RT-PCRs: miR-92a-3p/NEFM, p = 0.0052; miR-125b-5p/NEFM, p = 0.0429; miR-9-5p/NEFH, p = 0.0431; miR-20b-5p/NEFH, p = 0.0518; miR-92a-3p/NEFH, p = 0.0003; miR-223-3p/NEFH, p < 0.001; miR-519d-3p/NEFH, p = 0.0903)

Fig. 5

MiRNAs directly regulate luciferase transcripts linked to NEFM or NEFH 3’UTRs. HEK293T cells were co-transfected with a reporter plasmid containing mutant NEFM (a) or NEFH (b) 3’UTRs and miRNA mimics. Reporter gene assays were performed 24 h after transfection. Data are expressed as relative change and plotted in logarithmic scale. All experiments were performed in triplicate. Result are shown as mean ± SEM (One-way ANOVA followed by Tukey’s post hoc test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, relative to the pmirGLO vector control). MiR-92a-3p/NEFM, miR-125b-5p/NEFM, miR-9-5p/NEFH, miR-20b-5p/NEFH, miR-92a-3p/NEFH and miR-223-3p/NEFH, p < 0.0001)

A group of ALS-linked miRNAs regulate a luciferase reporter linked to NEFM or NEFH 3’UTRs. HEK293T cells were co-transfected with a reporter plasmid containing NEFM or NEFH 3’UTRs and miRNA mimics. a, b Reporter gene assays were performed 24 h after transfection. Data are expressed as relative change and plotted in logarithmic scale. c, d Relative quantitative RT-PCRs were performed after RNA extraction, 24 h post-transfection. Data are expressed as relative mRNA level change and plotted in logarithmic scale. All experiments were performed in triplicate. Results are shown as mean ± SEM (Student t-test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, relative to the pmirGLO vector control). Reporter gene assays: miR-92a-3p/NEFM, p < 0.0001; miR-125b-5p/NEFM, p = 0.0005; miR-let-7a/NEFM, p = 0.6015; miR-9-5p/NEFH, miR-20b-5p/NEFH, miR-92a-3p/NEFH and miR-223-3p/NEFH, p < 0.0001; miR-519d-3p/NEFH, p = 0.0723; miR-let-7a/NEFH, p = 0.0893. RT-PCRs: miR-92a-3p/NEFM, p = 0.0052; miR-125b-5p/NEFM, p = 0.0429; miR-9-5p/NEFH, p = 0.0431; miR-20b-5p/NEFH, p = 0.0518; miR-92a-3p/NEFH, p = 0.0003; miR-223-3p/NEFH, p < 0.001; miR-519d-3p/NEFH, p = 0.0903) MiRNAs directly regulate luciferase transcripts linked to NEFM or NEFH 3’UTRs. HEK293T cells were co-transfected with a reporter plasmid containing mutant NEFM (a) or NEFH (b) 3’UTRs and miRNA mimics. Reporter gene assays were performed 24 h after transfection. Data are expressed as relative change and plotted in logarithmic scale. All experiments were performed in triplicate. Result are shown as mean ± SEM (One-way ANOVA followed by Tukey’s post hoc test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, relative to the pmirGLO vector control). MiR-92a-3p/NEFM, miR-125b-5p/NEFM, miR-9-5p/NEFH, miR-20b-5p/NEFH, miR-92a-3p/NEFH and miR-223-3p/NEFH, p < 0.0001) Finally, considering the reduced expression of this group of 5 miRNAs in ALS spinal cords and the down-regulatory function they showed on NEFM and NEFH, we should expect an increase of NEFM and NEFH transcript and protein levels in ALS spinal cord tissue compared to controls. Consistent with this, we observed an increase in both NEFM and NEFH transcript and protein levels in ALS ventral lumbar spinal cords (Fig. 6a, b and c).
Fig. 6

NEFM and NEFH transcript and protein levels are increased in spinal cord of ALS patients. (a) Real-time PCR using TaqMan and (b) Western blots were performed using ventral lumbar spinal cord samples of controls and ALS patients. (c) Quantification of Western blots in (b). Protein levels were normalized to GAPDH. Data was expressed as the mean ± SEM (Student t-test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05. Real-time PCR: NEFM, p = 0.0027: NEFH, p = 0.0239. Western blot: NFM, p = 0.0238; NFH, p = 0.4762)

NEFM and NEFH transcript and protein levels are increased in spinal cord of ALS patients. (a) Real-time PCR using TaqMan and (b) Western blots were performed using ventral lumbar spinal cord samples of controls and ALS patients. (c) Quantification of Western blots in (b). Protein levels were normalized to GAPDH. Data was expressed as the mean ± SEM (Student t-test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05. Real-time PCR: NEFM, p = 0.0027: NEFH, p = 0.0239. Western blot: NFM, p = 0.0238; NFH, p = 0.4762)

Discussion

In this study we have shown that a small group of miRNAs that are dysregulated in the spinal cord of ALS patients directly regulate NEFM and NEFH mRNA stability and that this is associated with an increase in NFM and NFH protein levels in ALS spinal cord homogenates compared to neurological intact control spinal cord homogenates. The post-transcriptional control of NF transcripts is critical for establishing, consolidating and maintaining normal levels of NF proteins. The stoichiometry of NF subunits has to be tightly controlled to promote axonal outgrowth, control axon caliber and avoid the formation of NF aggregates, axonal degeneration and neuronal death [4, 18]. The regulation of NF transcripts expression occurs at multiple levels. It has been reported that splicing of the last intron of Xenopus NEFM increases nucleocytoplasmic export of the transcript which allows for robust gene expression [19]. Another level of regulation is at the mRNA transport. One study observed that the mRNAs of each NF subunit are present and translated within intact and regenerating rat sciatic nerve, demonstrating that NF transcripts are transported through axons [20]. At the final stage of mRNA regulation, it has been shown that the RNA-binding protein HuB increases the translation of NEFM transcript [21]. mRNA stability is the regulatory process of NF transcripts most extensively studied in which multiple trans-acting factors participate. In mice, it has been shown that the RNA-binding protein p190RhoGEF stabilizes and that glycolytic isoenzymes aldolases A and C directly destabilizes NEFL mRNA [22, 23]. Our previous studies have shown that the stability of NEFL is regulated by ALS-associated RNA-binding proteins. Mutant copper/zinc superoxide dismutase (mtSOD1) and Rho Guanine Nucleotide Exchange Factor (RGNEF; the human homologue of p190RhoGEF) mediate the destabilization and TAR DNA binding protein 43 kDa (TDP-43) the stabilization of NEFL mRNA [24-26]. In addition, fused in sarcoma/translocated in liposarcoma (FUS/TLS), another ALS-associated protein, has been shown to bind to murine NEFL, NEFM and NEFH transcripts [27]. The most prominent mechanism of RNA mediated gene silencing involves the interaction of miRNAs with their target mRNAs in which most, but not all, interactions between the miRNA and MREs leads to a degradation of the mRNA. Previously, we and others have observed a massive down-regulation of miRNAs in ALS spinal cord [11, 12, 17]. We also showed that three miRNAs that are dysregulated in ALS, miR-146a*, miR-524-5p and miR-582-3p, regulate levels of NEFL mRNA [9]. In this paper we extended our study to miRNAs responsible for NEFM and NEFH post-transcriptional regulation. We created a list of miRNAs that are down-regulated in ALS spinal cord and that also possess MREs within NEFM and NEFH 3’UTRs. From the published literature, we observed that two miRNAs of this group (miR-9 and miR-125b-5p) were confirmed to be reduced in ALS spinal cord [11, 12]. We established that a small group of ALS-linked miRNAs (miR-9-5p, miR-20b-5p, miR-92a-3p, miR-125b-5p and miR-223-3p) directly down-regulate human NEFM and NEFH mRNA levels, an effect that is translated into a reduction of NFM and NFH protein levels within spinal cord homogenates. From this group of miRNAs that regulate NEFM and NEFH mRNA levels, only miR-9 has been reported to have a role in neuronal function. More specifically, by regulating several targets including OC1, FoxP1, MAP1B, and MCPIP1, miR-9 is critical for motor neuron development, function and survival [28]. As these group of miRNAs that regulate NFM and NFH are reduced in spinal cord of ALS tissue, we predicted that the net effect would be an increase of NFM and NFH protein levels in ALS-spinal cords. Several groups have shown that NFL, NFM and/or p-NFH levels are increased in biological fluids of ALS patients [29-33], but there are no reports of NFs protein levels in spinal cord tissue. In this study we showed that both NFM and NFH levels are increased in ventral lumbar spinal cord of ALS patients compared to controls. This observation is in agreement with the increased in NEFM and NEFH transcripts in ALS ventral lumbar spinal cord homogenates that we observed here using real-time PCR and reported previously using RNase protection assay [34]. A selective reduction of NEFL steady state mRNA levels in spinal motor neurons of ALS patients has been well documented [13, 14, 35], a finding that we have proposed is due to alterations in the expression of in NEFL-linked miRNAs [9]. In concert with the observations of this study, we hypothesize that in ALS spinal cords the sustained dysregulation in time of the expression of groups of miRNAs that control NF levels fundamentally alters the expression of all three NF transcripts in a manner that induces an alteration in the stoichiometry of the individual NF proteins, favoring the formation of pathological NCIs. While this hypothesis supports the critical role of the alteration of miRNA expression in ALS, miRNAs alone are not the sole mediators of RNA stability. Indeed, understanding the fundamental relationship between alterations in RNA-binding proteins and how this interacts with alterations in miRNAs expression will be critical to understanding the process of perturbed RNA-mediated gene silencing which appears to lie at the core of a majority of ALS cases.
  35 in total

1.  p190RhoGEF Binds to a destabilizing element in the 3' untranslated region of light neurofilament subunit mRNA and alters the stability of the transcript.

Authors:  R Cañete-Soler; J Wu; J Zhai; M Shamim; W W Schlaepfer
Journal:  J Biol Chem       Date:  2001-07-02       Impact factor: 5.157

2.  Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.

Authors:  Emily Feneberg; Patrick Oeckl; Petra Steinacker; Federico Verde; Christian Barro; Philip Van Damme; Elizabeth Gray; Julian Grosskreutz; Claude Jardel; Jens Kuhle; Sonja Koerner; Foudil Lamari; Maria Del Mar Amador; Benjamin Mayer; Claudia Morelli; Petra Muckova; Susanne Petri; Koen Poesen; Joost Raaphorst; François Salachas; Vincenzo Silani; Beatrice Stubendorff; Martin R Turner; Marcel M Verbeek; Jochen H Weishaupt; Patrick Weydt; Albert C Ludolph; Markus Otto
Journal:  Neurology       Date:  2017-12-06       Impact factor: 9.910

3.  TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein.

Authors:  Michael J Strong; Kathryn Volkening; Robert Hammond; Wencheng Yang; Wendy Strong; Cheryl Leystra-Lantz; Christen Shoesmith
Journal:  Mol Cell Neurosci       Date:  2007-03-20       Impact factor: 4.314

4.  Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis.

Authors:  Fiona M Menzies; Andrew J Grierson; Mark R Cookson; Paul R Heath; Janine Tomkins; Denise A Figlewicz; Paul G Ince; Pamela J Shaw
Journal:  J Neurochem       Date:  2002-09       Impact factor: 5.372

5.  Characterization of mammalian neurofilament triplet proteins. Subunit stoichiometry and morphology of native and reconstituted filaments.

Authors:  D Scott; K E Smith; B J O'Brien; K J Angelides
Journal:  J Biol Chem       Date:  1985-09-05       Impact factor: 5.157

6.  Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurons.

Authors:  C Bergeron; K Beric-Maskarel; S Muntasser; L Weyer; M J Somerville; M E Percy
Journal:  J Neuropathol Exp Neurol       Date:  1994-05       Impact factor: 3.685

7.  pNfH is a promising biomarker for ALS.

Authors:  Jeban Ganesalingam; Jiyan An; Robert Bowser; Peter M Andersen; Christopher E Shaw
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2012-10-22       Impact factor: 4.092

8.  Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis.

Authors:  Anna Häggmark; Maria Mikus; Atefeh Mohsenchian; Mun-Gwan Hong; Björn Forsström; Beata Gajewska; Anna Barańczyk-Kuźma; Mathias Uhlén; Jochen M Schwenk; Magdalena Kuźma-Kozakiewicz; Peter Nilsson
Journal:  Ann Clin Transl Neurol       Date:  2014-07-14       Impact factor: 4.511

Review 9.  MotomiRs: miRNAs in Motor Neuron Function and Disease.

Authors:  Zachary C E Hawley; Danae Campos-Melo; Cristian A Droppelmann; Michael J Strong
Journal:  Front Mol Neurosci       Date:  2017-05-04       Impact factor: 5.639

10.  Analysis of microRNA from archived formalin-fixed paraffin-embedded specimens of amyotrophic lateral sclerosis.

Authors:  Koichi Wakabayashi; Fumiaki Mori; Akiyoshi Kakita; Hitoshi Takahashi; Jun Utsumi; Hidenao Sasaki
Journal:  Acta Neuropathol Commun       Date:  2014-12-14       Impact factor: 7.801

View more
  8 in total

1.  BraInMap Elucidates the Macromolecular Connectivity Landscape of Mammalian Brain.

Authors:  Reza Pourhaghighi; Peter E A Ash; Sadhna Phanse; Florian Goebels; Lucas Z M Hu; Siwei Chen; Yingying Zhang; Shayne D Wierbowski; Samantha Boudeau; Mohamed T Moutaoufik; Ramy H Malty; Edyta Malolepsza; Kalliopi Tsafou; Aparna Nathan; Graham Cromar; Hongbo Guo; Ali Al Abdullatif; Daniel J Apicco; Lindsay A Becker; Aaron D Gitler; Stefan M Pulst; Ahmed Youssef; Ryan Hekman; Pierre C Havugimana; Carl A White; Benjamin C Blum; Antonia Ratti; Camron D Bryant; John Parkinson; Kasper Lage; Mohan Babu; Haiyuan Yu; Gary D Bader; Benjamin Wolozin; Andrew Emili
Journal:  Cell Syst       Date:  2020-04-22       Impact factor: 10.304

2.  MiR-125a-5p Regulates Vitamin D Receptor Expression in a Mouse Model of Experimental Autoimmune Encephalomyelitis.

Authors:  Han-Chun Long; Rui Wu; Chun-Feng Liu; Fei-Long Xiong; Zu Xu; Dian He; Yi-Fan Zhang; Bing Shao; Ping-An Zhang; Guang-Yin Xu; Lan Chu
Journal:  Neurosci Bull       Date:  2019-08-19       Impact factor: 5.203

Review 3.  Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases.

Authors:  Giulia Gentile; Giovanna Morello; Valentina La Cognata; Maria Guarnaccia; Francesca Luisa Conforti; Sebastiano Cavallaro
Journal:  J Pers Med       Date:  2022-05-10

4.  MiRNA-494 enhances M1 macrophage polarization via Nrdp1 in ICH mice model.

Authors:  Gaohai Shao; Changlong Zhou; Kunlong Ma; Wang Zhao; Qijiang Xiong; Ling Yang; Zhongyan Huang; Zhao Yang
Journal:  J Inflamm (Lond)       Date:  2020-04-25       Impact factor: 4.981

Review 5.  New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis.

Authors:  Frances Theunissen; Phillip K West; Samuel Brennan; Bojan Petrović; Kosar Hooshmand; P Anthony Akkari; Matt Keon; Boris Guennewig
Journal:  Transl Neurodegener       Date:  2021-11-15       Impact factor: 8.014

6.  Microglia Influence Neurofilament Deposition in ALS iPSC-Derived Motor Neurons.

Authors:  Reilly L Allison; Jacob W Adelman; Jenica Abrudan; Raul A Urrutia; Michael T Zimmermann; Angela J Mathison; Allison D Ebert
Journal:  Genes (Basel)       Date:  2022-01-27       Impact factor: 4.096

7.  Intronic NEFH variant is associated with reduced risk for sporadic ALS and later age of disease onset.

Authors:  Frances Theunissen; Ryan S Anderton; Frank L Mastaglia; Ian James; Richard Bedlack; P Anthony Akkari
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

Review 8.  miRNA-Dependent Control of Homeostatic Plasticity in Neurons.

Authors:  Sandra Dubes; Alexandre Favereaux; Olivier Thoumine; Mathieu Letellier
Journal:  Front Cell Neurosci       Date:  2019-12-05       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.